BDH Industries is a pharmaceutical formulator that makes finished medicines and sells them to governments, NGOs and healthcare buyers across more than 30 countries, while also running a small wind-power business on the side. The company was founded in Mumbai in 1990 and has been led ever since by second-generation entrepreneurs with deep industry experience - its Chairperson has over 60 years in pharma and its Joint Managing Director over 47. The recurring approach is to manufacture a wide therapeutic range under one WHO-GMP-accredited roof, sell at economical rates to institutional buyers abroad, and reinvest in adjacent assets - first a DSIR-approved R&D centre, then two wind turbines in Rajasthan - without ever taking on a subsidiary.
Business segments
Two engines at different stages - a pharmaceutical formulations business that serves both export and domestic markets from a single Mumbai plant, and a small renewable-energy operation selling wind power on the open exchange - each built with the cash flows of the one before.
1. Pharmaceutical formulations: where the company earns its living
A single WHO-GMP plant in Mumbai makes finished-dosage medicines across more than 30 therapeutic classes and ships them to over 30 countries, with export and domestic sales each contributing roughly half of product revenue.
- One plant, many medicines - the manufacturing facility at Kandivli, Mumbai, produces finished-dosage-form formulations spanning analgesics, anti-TB drugs, anticancer therapies, antidiabetics, cardiovascular medicines, corticosteroids, vitamins and more than 20 other therapeutic categories, all under one roof.
- Sold to governments and NGOs, not just distributors - the company explicitly targets Ministries of Health, Departments of Health Services and international NGOs, positioning itself as an affordable supplier with value-added services for Rest of the World markets.
- Export and domestic are near-equal legs - in FY 2024-25, export sales were ₹30.96 crore and domestic sales were ₹35.55 crore, so the business does not depend on any single geography.
- R&D is a tax-approved cost-reduction engine - the in-house R&D centre is recognised by DSIR, Government of India, and approved for weighted tax deduction under Section 35(2AB) of the Income Tax Act; its work focuses on novel drug-delivery systems, new dosage forms, process improvements and yield gains rather than discovery of new molecules.
- Commodity-light, so input costs are stable - the company does not consume large quantities of commodities in manufacturing and does not hedge, which means it is not materially exposed to the raw-material price swings that trouble bulk-drug makers.
2. Renewable energy: a small wind-power bet that finally turned on
Two 0.8 MW wind turbines in Jaisalmer sell electricity on the Indian Energy Exchange after years of waiting for a commercial pathway - a side business that generated 1.85 million units in its first full year.
- Built, then stalled, then switched on - the turbines were installed and sitting in the gross block at ₹8.12 crore as far back as FY22, but no depreciation was charged because they could not be put to commercial use; a Power Purchase Agreement with the Rajasthan government never materialised, so the company eventually signed a commercial agreement with Jodhpur DISCOM in February 2024 and commissioned the plant under open-access third-party sale.
- Sold on the exchange, not to a single buyer - the electricity generated is sold on the Indian Energy Exchange, which means the company takes the prevailing market price rather than locking into a long-term fixed-rate PPA.
- Small but now revenue-generating - in FY 2024-25, the two turbines together produced 18,52,250 kWh and earned ₹1.04 crore in revenue, making this a modest but tangible second income stream after years of being a non-performing asset.
Group structure and partners
A tightly held, subsidiary-free company run by a six-member board where the founding family holds just under half the equity and the two most senior executives have been directors since incorporation.
- No subsidiaries, one related party - the company has no subsidiary and only one related corporate entity, BDH Healthcare Pvt. Ltd., in which the Chairperson is a director.
- Founders still run the shop - Ms. Jayashree Nair (Chairperson & Managing Director, over 60 years in pharma) and Mr. S. C. Kachhara (Joint Managing Director & CFO, over 47 years in pharma) have both been on the board since the company was incorporated in 1990; Mr. Kachhara was re-designated as Managing Director in May 2025.
- Promoters hold 49.66% - as of 31st March 2025, the promoter group along with directors and relatives owned just under half of the 57.57 lakh outstanding shares, with 98.54% of all shares held in dematerialised form.
- Three independent directors on a six-member board - the board includes Ms. Karthika Nair (Non-Executive, related to the Chairperson) and three independents, one of whom was appointed effective April 2024.